The class action lawsuit charges that Keryx and certain of its officers and directors made false and misleading statements or omissions regarding the Company's business operations. Specifically, that Keryx failed to disclose that it was experiencing production-related difficulties and that, because of these issues, its Auryxia inventory would and did become depleted, causing the company to halt the drug's distribution and withdraw Keryx's 2016 financial guidance.
If you purchased or otherwise acquired Keryx securities prior to August 1, 2016, you may be a member of the class and eligible to participate in litigation. To learn more about your options or if you have any questions about the litigation, please contact Bradley Vettraino or Steven Harte at (617) 398-5600, by email at email@example.com or firstname.lastname@example.org, or visit www.blockesq.com/keryx.
Confidentiality to whistleblowers or others with information relevant to the lawsuit is assured.
Block & Leviton LLP is a Boston-based law firm representing investors nationwide. The firm's lawyers have collectively been prosecuting securities cases on behalf of individual and institutional investors for over 100 years, and have recovered billions of dollars on their behalf. Block & Leviton's investigations into corporate wrongdoing were recently covered by the New York Times.
This notice may constitute attorney advertising.
Block & Leviton LLP
Bradley J. Vettraino
Steven P. Harte
155 Federal Street, Suite 400
Boston, MA 02110
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/block--leviton-llp-announces-the-filing-of-a-class-action-lawsuit-against-keryx-biopharmaceuticals-inc-for-violations-of-the-federal-securities-laws-300311077.html
SOURCE Block & Leviton LLP